Cyanvac develops vaccines using parainfluenza virus 5 (PIV5) as a vector. The company is currently focused on developing robust, intranasal vaccines that are easy to administer, easy to transport and easy to manufacture.
Two of Cyanvac’s vaccine candidates are scheduled to enter clinical testing beginning in 2021, including an intrasal vaccine to serve as a booster for protecting against SARS-CoV-2 infection. The candidate was selected for the trail by an academic consortium that has run government-funded trials for other COVID-19 vaccines, and the clinical evaluation will be conducted at no cost to Cyanvac.
Cyanvac also has vaccine candidates for respiratory syncytial virus (RSV), norovirus and Lyme Disease.
Company website: Cyanvac
Back to companies
Employees: 11-50